Skip to main content

Table 5 S. aureus bacteremia (SAB)—estimated days of therapy per 100 bed days: one year prior to and one year after implementing selective reporting

From: Staphylococcus aureus - selective reporting of antibiogram results and its impact on antibiotic use: Interventional study with a reference group on the effect of switching from non-selective to selective antibiotic reporting

Antibiotics

Prior to implementing selective reporting

n = 86, BD = 943

After implementing selective reporting

n = 81, BD = 946

DOT per 100 BD after vs. prior to#

pat/ DOT/DOT per 100 BD (95%-CI)*

pat/ DOT/DOT per 100 BD (95%-CI)*

IRR (95%-CI)

p

Selectively reported antibiotics

 Flucloxacillin iv + Cefazolin iv

50 / 494 / 52.4 (42.8; 62.0)

72 / 706 / 74.6 (67.5; 81.8)

1.42 (1.16; 1.75)

0.001

 Cefalexin po

2 / 5 / 0.5 (−0.2; 1.3)

3 / 9 / 1.0 (−0.3; 2.2)

1.79 (0.27; 12.01)

–

 Trimethoprim-sulfamethoxazole

1 / 3 / 0.3 (−0.3; 0.9)

2 / 5 / 0.5 (−0.3; 1.4)

1.66 (0.13; 20.94)

–

 Clindamycin iv/po

8 / 47 / 5.0 (0.9; 9.0)

6 / 28 / 3.0 (−0.3; 6.2)

0.59 (0.15; 2.34)

0.457

 Sum of above named selectively reported antibiotics

53 / 549 / 58.2 (48.4; 68.1)

74 / 748 / 79.1 (71.4; 86.7)

1.36 (1.12; 1.65)

0.002

Combination therapy only

 Gentamicin + Tobramycin + Amikacin iv

6 / 32 / 3.4 (0.3; 6.5)

5 / 29 / 3.1 (0.3; 5.8)

0.90 (0.25; 3.28)

0.877

 Rifampin iv/po

15 / 124 / 13.1 (6.6; 19.7)

9 / 92 / 9.7 (3.3; 16.2)

0.74 (0.32; 1.70)

0.476

 Fosfomycin iv

2 / 8 / 0.8 (−0.5; 2.2)

1 / 7 / 0.7 (−0.7; 2.2)

0.87 (0.07; 10.47)

–

No longer reported antibiotics

 Penicillin G + Ampicillin/Amoxicillin iv

2 / 11 / 1.2 (−0.4; 2.8)

1 / 1 / 0.1 (−0.1; 0.3)

0.09 (0.01; 1.00)

–

 Ampicillin-sulbactam + Amoxicillin-clavunate iv/po

18 / 69 / 7.3 (3.3; 11.3)

2 / 4 / 0.4 (−0.2; 1.0)

0.06 (0.01; 0.25)

 < 0.001

 Piperacillin-tazobactam

27 / 128 / 13.6 (7.6; 19.5)

34 / 158 / 16.7 (10.4; 23.0)

1.23 (0.69; 2.19)

0.481

 Cefuroxime iv/po

10 / 68 / 7.2 (2.2; 12.2)

2 / 14 / 1.5 (−1.0; 4.0)

0.21 (0.03; 1.28)

0.090

 Ceftriaxone iv + Ceftazidime iv + Cefpodoxime po

10 / 46 / 4.9 (1.3; 8.5)

10 / 28 / 3.0 (0.5; 5.4)

0.61 (0.20; 1.84)

0.378

 Imipenem-cilastatin iv + Meropenem iv

11 / 49 / 5.2 (1.6; 8.8)

14 / 69 / 7.3 (3.2; 11.4)

1.40 (0.58; 3.42)

0.455

 Ciprofloxacin + Levofloxacin + Moxifloxacin iv/po

14 / 78 / 8.3 (3.7; 12.9)

12 / 79 / 8.4 (3.1; 13.6)

1.01 (0.44; 2.33)

0.982

 Vancomycin iv

13 / 44 / 4.7 (1.8; 7.5)

7 / 31 / 3.3 (−0.3; 6.8)

0.70 (0.20; 2.43)

0.577

 Linezolid iv/po

2 / 13 / 1.4 (−0.9; 3.7)

2 / 8 / 0.8 (−0.6; 2.3)

0.61 (0.06; 6.76)

–

 Sum of above named no longer reported antibiotics

70 / 506 / 53.7 (44.6; 62.7)

58 / 392 / 41.4 (31.4; 51.5)

0.77 (0.57; 1.04)

0.087

 Patients with therapy adaption to intravenous flucloxacillin/cefazolin on day 2–4, n (%)

36 (41.9%)

62 (76.5%)

 

< 0.001 ##

  1. Follow up to a maximum of 14 bed days per patient (except early exit because of death, discharge or hospital transfer)
  2. *Pat/ DOT/DOT per 100 BD (95%-CI): number of patients, days of therapy (DOT), days of therapy per 100 bed days (BD) with 95%-conifdence interval estimated by Poisson regression;
  3. #Poisson regression, incidence rate ratio (IRR) with 95%-confidence interval (CI) and p-value (p), p-values < 0.05 in bold. In case of less than 5 patients in both periods no statistical test was performed
  4. ##Exact Fisher-test
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us